Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Beam Therapeutics Inc (NASDAQ: BEAM) was $24.43 for the day, down -1.73% from the previous closing price of $24.86. In other words, the price has decreased by -$1.73 from its previous closing price. On the day, 0.6 million shares were traded. BEAM stock price reached its highest trading level at $25.05 during the session, while it also had its lowest trading level at $24.015.
Ratios:
Our analysis of BEAM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.81 and its Current Ratio is at 5.81. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 23, 2024, initiated with a Buy rating and assigned the stock a target price of $80.
On January 29, 2024, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $38 to $40.
BofA Securities Downgraded its Buy to Neutral on December 15, 2023, while the target price for the stock was maintained at $35.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 02 ’24 when Simon Amy sold 748 shares for $22.95 per share. The transaction valued at 17,167 led to the insider holds 68,805 shares of the business.
Simon Amy sold 502 shares of BEAM for $11,928 on Jul 01 ’24. The Chief Medical Officer now owns 69,553 shares after completing the transaction at $23.76 per share. On Jun 27 ’24, another insider, Evans John M., who serves as the CEO of the company, sold 60,000 shares for $24.50 each. As a result, the insider received 1,470,156 and left with 998,343 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 2013413120 and an Enterprise Value of 1088441216. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.71 while its Price-to-Book (P/B) ratio in mrq is 2.36. Its current Enterprise Value per Revenue stands at 3.087 whereas that against EBITDA is -6.682.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $49.50, while it has fallen to a 52-week low of $16.95. The 50-Day Moving Average of the stock is -5.06%, while the 200-Day Moving Average is calculated to be -10.69%.
Shares Statistics:
BEAM traded an average of 1.27M shares per day over the past three months and 828450 shares per day over the past ten days. A total of 81.63M shares are outstanding, with a floating share count of 71.56M. Insiders hold about 6.58% of the company’s shares, while institutions hold 81.81% stake in the company. Shares short for BEAM as of 1722384000 were 11621310 with a Short Ratio of 9.13, compared to 1719532800 on 11796299. Therefore, it implies a Short% of Shares Outstanding of 11621310 and a Short% of Float of 18.47.
